State of Migraine Care and Therapeutics: Richard B. Lipton, MD
The director of the Montefiore Headache Center provided an overview of the recent advances in migraine medications and how it has translated to improved care. [WATCH TIME: 2 minutes]
WATCH TIME: 2 minutes
"On the acute treatment side, gepants have a lot of strength. They don’t have the cardiovascular contraindications and precautions of triptans so that they can be used safely in a broader group of patients."
With numerous therapeutic advances in the past decade, some, including Richard B. Lipton, MD, argue that there has not been a better time to be treating patients with migraine. The toolbox clinicians have at their disposal has grown in several positive ways, mainly because of the boom in molecules designed to target calcitonin gene-related peptide (CGRP). In May 2021, more groundbreaking progress was made, as the FDA approved rimegepant (Nurtec ODT; Biohaven) as the first treatment for both acute and preventive uses.
Lipton, director of the Montefiore Headache Center, was a trial investigator in several analyses of which included zavegepant (BHV-3500; Biohaven), rimegepant, ubrogepant (Ubrevly; AbbVie), and much more, presented at the recently concluded 2022 American Headache Society (AHS) Annual Meeting, June 9-12, in Denver, Colorado. In an interview with NeurologyLive®, Lipton discussed the specific ways the treatment landscape has improved, how patients have benefitted, and the advent of new administration methods.
Click here for more coverage of AHS 2022.
